Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Virtual Conference
July 27, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical...
Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders
July 21, 2020 16:45 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it is...
Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics
July 16, 2020 09:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Dissecting the Immune Response to SARS-CoV-2 in Healthy Recovered or Asymptomatic Volunteers May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics Potential for Human Monoclonal...
Tonix Pharmaceuticals Holding Corp. Closes $10.5 Million Common Stock Registered Direct Offering
July 15, 2020 17:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 15, 2020 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of...
Tonix Pharmaceuticals Holding Corp. Prices $10,500,000 Common Stock Offering
July 13, 2020 13:11 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered...
Tonix Pharmaceuticals Enters into Research and Exclusive License Option Agreement with Kansas State University to Develop Vaccine Against COVID-19
July 13, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Research to Develop Live Replicating Vaccine (TNX-2300) to Protect Against COVID-19 Based on Bovine Parainfluenza Virus TNX-2300 Will Be Tonix’s Second Live Replicating Virus Vaccine Platform ...
Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia
July 10, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Target Enrollment Completed Ahead of Schedule Topline Data Expected Fourth Quarter 2020 Results of Interim Analysis from the First 50 Percent of Participants Expected in September 2020 NEW YORK,...
Tonix Pharmaceuticals Plans Massachusetts R&D Facility to Accelerate Clinical Development of Vaccines and Protein-Based Therapeutics
July 07, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Tonix's Advanced Development Center Will House Laboratories Dedicated to Process and Analytical Development NEW YORK, July 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:...
Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule
June 29, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Topline Results Expected Fourth Quarter 2020 Due to Faster than Previously Projected Enrollment Completion of Trial Enrollment Anticipated Early Third Quarter 2020 Interim Results from the First 50...
Tonix Pharmaceuticals Announces Results from Preclinical Study of TNX-1700 Presented in a Poster at AACR Virtual Annual Meeting 2020
June 22, 2020 09:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-1700 (Stabilized Recombinant Trefoil Factor 2) (rTFF2-CTP) Enhances Anti-tumor Activity of PD-1 blockade in Mouse Models of Colorectal Cancer NEW YORK, June 22, 2020 (GLOBE NEWSWIRE) -- Tonix...